Pancreatic Cancer Research

ResearcherKanazawa UniversityActive in the last 2 years

Koushiro Ohtsubo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4490-4306; OpenAlex author ID A5011925647, A5066902370. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 8

  1. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Co-author DOI 10.1038/s41416-024-02834-0↗
  2. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02189-y↗
  3. Risk factors for interstitial lung disease induced by gemcitabine plus albumin-bound paclitaxel therapy in pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1186/s40780-021-00236-5↗
  4. Clinical outcome of patients with inoperable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus Nab‑paclitaxel as a first‑line therapy: A retrospect… Co-author DOI 10.3892/mi.2021.8↗
  5. P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma. Co-author DOI 10.1007/s00262-014-1529-8↗
  6. Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000168↗
  7. Multiple factors influencing the release of hTERT mRNA from pancreatic cancer cell lines in in vitro culture. Co-author DOI 10.1042/cbi20090471↗
  8. Endoscopic findings of upper gastrointestinal lesions in patients with pancreatic cancer. Co-author DOI 10.6092/1590-8577/749↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kentaro Sudo · 2 shared papers, 2023–2024 · strength 0.28
  2. Nobuhisa Matsuhashi · 2 shared papers, 2023–2024 · strength 0.28
  3. Kumiko Umemoto · 2 shared papers, 2023–2024 · strength 0.28
  4. Nobumasa Mizuno · 2 shared papers, 2023–2024 · strength 0.28
  5. Masayuki Furukawa · 2 shared papers, 2023–2024 · strength 0.28
  6. Masafumi Ikeda · 2 shared papers, 2023–2024 · strength 0.28
  7. Naohiro Okano · 2 shared papers, 2023–2024 · strength 0.28
  8. Yasuyuki Kawamoto · 2 shared papers, 2023–2024 · strength 0.28
  9. Shinji Itoh · 2 shared papers, 2023–2024 · strength 0.28
  10. Makoto Ueno · 2 shared papers, 2023–2024 · strength 0.28
  11. Chigusa Morizane · 2 shared papers, 2023–2024 · strength 0.28
  12. Takeshi Terashima · 2 shared papers, 2014–2022 · strength 0.20
  13. Seiji Yano · 3 shared papers, 2012–2021 · strength 0.20
  14. Rikako Ueda · 1 shared paper, 2022 · strength 0.16
  15. Yoshimichi Sai · 1 shared paper, 2022 · strength 0.16
  16. Akinori Asagi · 1 shared paper, 2024 · strength 0.15
  17. Masato Ozaka · 1 shared paper, 2024 · strength 0.15
  18. Toru Otsuru · 1 shared paper, 2023 · strength 0.13
  19. Yu Sunakawa · 1 shared paper, 2023 · strength 0.13
  20. Hiroyuki Sakaguchi · 1 shared paper, 2021 · strength 0.12
  21. Shuichi Kaneko · 1 shared paper, 2014 · strength 0.04
  22. Tetsuo Ohta · 1 shared paper, 2014 · strength 0.04
  23. Gensaku Okada · 1 shared paper, 2012 · strength 0.03
  24. Yoshiharu Motoo · 1 shared paper, 2012 · strength 0.03
  25. Norio Sawabu · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.